News Granules India Reports Mixed Q4 Performance Granules India's recent financial report for Q4 and FY2024 reflects a blend of outcomes.
News Dr. Lal PathLabs Reports Impressive Financial Performance in Q1 FY24 Dr. Lal PathLabs reports robust Q1 FY24 results with a 9.7% rise in non-COVID revenue, 28.4% normalized EBITDA margin, and 15.4% PAT margin.
